Magnolia Medical has announced the introduction of Magnolia Analytics, a technology-enabled service solution designed to streamline data capture and assess the clinical and cost-effectiveness of sepsis misdiagnosis prevention.

Developed in collaboration with several hospital systems in the US, the end-to-end, software-driven solution is aimed at supporting hospitals and healthcare systems in achieving the new national standard of care for blood culture contamination performance.

The Magnolia Analytics platform is a response to the need for robust quantification of the clinical and economic value created by reducing blood culture contamination.

This aligns with the recent CDC guidelines, which emphasise the importance of accurate sepsis testing for patient safety and hospital financial efficiency.

Magnolia Medical CEO and co-founder Greg Bullington said: “In response to our customer’s clear unmet needs, we developed Magnolia Analytics as a custom, exclusive solution to support our hospitals in achieving and sustaining their blood culture contamination rates in line with the new benchmarks established by CDC and CLSI.

“The continued adoption of Steripath and Magnolia Medical’s Mission to ZERO programme at nearly 500 hospitals and healthcare systems to date across the US speaks to the impact of our technology solution. The addition of Magnolia Analytics enables transparent access to performance monitoring for hospital leadership.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Serving as the objective source, the platform can help in assessing the performance of unproven devices and interventions. This allows hospital systems to conduct an in-depth analysis of these solutions at the facility and patient level.

Bullington added: “Magnolia Analytics is an essential part of our Mission to ZERO solution, providing clinicians with confidence regarding the accuracy of blood culture results while giving our customers peace of mind that they will continually achieve validated, measurable, and sustained returns on their Steripath investment.”

Last year, Magnolia Medical secured 510(k) clearance from the US Food and Drug Administration for 19 new Steripath Micro configurations within its Initial Specimen Diversion Device product family.